INT9429

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 1991
Last Reported 2010
Negated 6
Speculated 1
Reported most in Body
Documents 18
Total Number 20
Disease Relevance 10.03
Pain Relevance 2.07

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Clcn1) transmembrane transport (Clcn1)
Anatomy Link Frequency
myoblasts 1
blood 1
plasma 1
muscle 1
posterior 1
Clcn1 (Mus musculus)
Pain Link Frequency Relevance Heat
Dopamine 6 98.96 Very High Very High Very High
Analgesic 13 98.92 Very High Very High Very High
noradrenaline 4 98.24 Very High Very High Very High
cINOD 13 94.08 High High
Catecholamine 6 93.92 High High
sSRI 7 91.60 High High
fluoxetine 1 77.36 Quite High
depression 1 75.72 Quite High
iatrogenic 2 75.00 Quite High
sodium channel 1 75.00 Quite High
Disease Link Frequency Relevance Heat
Adverse Drug Reaction 388 100.00 Very High Very High Very High
Renal Disease 25 100.00 Very High Very High Very High
Myotonia Congenita 6 100.00 Very High Very High Very High
Cardiomyopathy 6 100.00 Very High Very High Very High
Stress 10 95.56 Very High Very High Very High
Oliguria 56 93.68 High High
Anxiety Disorder 6 92.36 High High
Coronary Heart Disease 9 88.24 High High
Stroke 16 86.64 High High
Myocardial Infarction 11 86.20 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The plasma adrenaline (Adr) level also increased significantly, but the extent was smaller than that of NA or DA. 3.
Positive_regulation (increased) of Adr in plasma associated with dopamine and noradrenaline
1) Confidence 0.58 Published 1991 Journal J Auton Pharmacol Section Abstract Doc Link 2030107 Disease Relevance 0.53 Pain Relevance 0.72
Triciribine only gave a 1.2±0.2 fold increase in luciferase signal in CLCN1-luc WT myoblasts compared to DMSO treatment (p = 2.4 x 10-3), but this was not surprising given that these cells already spliced the reporter construct correctly.
Positive_regulation (increase) of CLCN1 in myoblasts
2) Confidence 0.44 Published 2010 Journal Current Chemical Genomics Section Body Doc Link PMC2874217 Disease Relevance 0 Pain Relevance 0.03
By plotting a histogram of relative activity of test compounds (Fig. 5C) a normal distribution with mean = 1.0 was observed and a hit rate of 0.26% was observed using a threshold of greater than 1.3 fold increase in CLCN1-luc signal above that of the DMSO negative control.
Positive_regulation (increase) of CLCN1
3) Confidence 0.41 Published 2010 Journal Current Chemical Genomics Section Body Doc Link PMC2874217 Disease Relevance 0.07 Pain Relevance 0
Antibiotic and analgesic drugs were the most common drug groups implicated in causing an ADR.
Positive_regulation (causing) of ADR associated with analgesic
4) Confidence 0.39 Published 1999 Journal Therapie Section Abstract Doc Link 10216442 Disease Relevance 0.30 Pain Relevance 0.14
Only 11 (8.5%) of patients suspected themselves that the drug might have caused the ADR.
Spec (might) Positive_regulation (caused) of ADR
5) Confidence 0.39 Published 1994 Journal Int J Clin Pharmacol Ther Section Abstract Doc Link 7881707 Disease Relevance 1.05 Pain Relevance 0.35
Mean arterial pressure was increased in Adr-P rats (137 +/- 2.5 vs. 95 +/- 3.2 mmHg in NP; P < 0.001).
Positive_regulation (increased) of Adr-P associated with renal disease
6) Confidence 0.30 Published 1992 Journal Am. J. Physiol. Section Abstract Doc Link 1415742 Disease Relevance 1.48 Pain Relevance 0
Every effort was made to recruit a maximum variation sample with a range of sociodemographic backgrounds by placing recruitment materials in a wide range of locations; however, given the difficulty we encountered in finding people that identified experiencing a NHP-related ADR, all those who met the inclusion criteria for the study were interviewed.
Positive_regulation (experiencing) of NHP-related ADR
7) Confidence 0.22 Published 2010 Journal BMC Complement Altern Med Section Body Doc Link PMC2847952 Disease Relevance 0 Pain Relevance 0
Patients suspected of experiencing an ADR were taking a mean of 8.2 (± 2.6) different medicines compared with those not having an ADR with a mean of 7.3 (± 2.1) medicines (p = 0.015).
Positive_regulation (experiencing) of ADR
8) Confidence 0.18 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661606 Disease Relevance 0.46 Pain Relevance 0
The two conjugates were found to have 4 to 7 molecules of ADR per molecule of p97 at an ADR concentration of 17 to 60.6 µg/ml.


Positive_regulation (molecules) of ADR
9) Confidence 0.18 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2424243 Disease Relevance 0 Pain Relevance 0
Expected frequencies calculation showed that with the high dose regime statins protected 12,577 out of 14,768 patients (85.2%) without causing ADR; this value was 12,597 out of 14,625 (86.1%) in the case of the low dose regime.
Neg (without) Positive_regulation (causing) of ADR associated with adverse drug reaction
10) Confidence 0.05 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2570485 Disease Relevance 0.42 Pain Relevance 0
The procedure is feasible whenever the total number of patients who responded to treatment favorably as well as the total number of patients who experienced ADR are reported; happily, authors do usually report these data.
Positive_regulation (experienced) of ADR associated with adverse drug reaction
11) Confidence 0.04 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2570485 Disease Relevance 0.34 Pain Relevance 0.05
In order to combine efficacy and safety in one easily understandable measure, results obtained from CRT may be divided into two categories: a) patients responding to treatment without suffering adverse drug reactions (ADR); and b) the remaining patients, i.e. the sum of those responding to the drug but suffering ADR, plus those resistant to the treatment but not suffering ADR, plus those resistant to the treatment and simultaneously suffering ADR.
Neg (without) Positive_regulation (suffering) of ADR associated with adverse drug reaction
12) Confidence 0.04 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2570485 Disease Relevance 0.85 Pain Relevance 0
In the case of more general analyses, an appropriate variable for safety may be the proportion of patients that discontinued drug treatment as a consequence of an ADR (the case of high v.s. low dose statins).
Positive_regulation (consequence) of ADR associated with adverse drug reaction
13) Confidence 0.04 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2570485 Disease Relevance 0.27 Pain Relevance 0.13
In order to combine efficacy and safety in one easily understandable measure, results obtained from CRT may be divided into two categories: a) patients responding to treatment without suffering adverse drug reactions (ADR); and b) the remaining patients, i.e. the sum of those responding to the drug but suffering ADR, plus those resistant to the treatment but not suffering ADR, plus those resistant to the treatment and simultaneously suffering ADR.
Neg (not) Positive_regulation (suffering) of ADR associated with adverse drug reaction
14) Confidence 0.04 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2570485 Disease Relevance 0.75 Pain Relevance 0
In order to combine efficacy and safety in one easily understandable measure, results obtained from CRT may be divided into two categories: a) patients responding to treatment without suffering adverse drug reactions (ADR); and b) the remaining patients, i.e. the sum of those responding to the drug but suffering ADR, plus those resistant to the treatment but not suffering ADR, plus those resistant to the treatment and simultaneously suffering ADR.
Neg (not) Positive_regulation (suffering) of ADR associated with adverse drug reaction
15) Confidence 0.04 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2570485 Disease Relevance 0.82 Pain Relevance 0
Leaving aside for a posterior analysis those aspects related to the severity of ADR, the number of patients responding to treatment without suffering ADR is unavailable in most published data sources, as mentioned above.
Neg (without) Positive_regulation (suffering) of ADR in posterior associated with adverse drug reaction
16) Confidence 0.04 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2570485 Disease Relevance 0.88 Pain Relevance 0
This is one of the rare cases in which the authors detailed the actual values of patients improved without suffering ADR; the authors compared an unknown test drug with a standard one jointly with hydrochlorothiazide to control blood pressure.
Neg (without) Positive_regulation (suffering) of ADR in blood associated with adverse drug reaction
17) Confidence 0.04 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2570485 Disease Relevance 0.35 Pain Relevance 0
Although specific drugs may be risk factors for side effects and drug interaction in elderly individuals, the most prevalent factor for the increase in ADR in this age group may be polypharmacy.
Positive_regulation (increase) of ADR
18) Confidence 0.01 Published 2005 Journal Environ Health Perspect Section Body Doc Link PMC1280410 Disease Relevance 0.28 Pain Relevance 0.36
ADR-cardiomyopathy was induced in 40 male Wistar rats weighing 230 ± 25g by the weekly administration of 2 mg/kg of ADR (supplied by Kyowa Hakko Kogyo Co.
Positive_regulation (induced) of ADR associated with cardiomyopathy
19) Confidence 0.01 Published 2005 Journal Yonsei Medical Journal Section Body Doc Link PMC2823060 Disease Relevance 0.63 Pain Relevance 0.08
The cause of increased excitability in autosomal dominant myotonia congenita (MyC) was studied in resealed greater than 3-cm long segments of muscle fibres from eight patients.
Positive_regulation (increased) of autosomal dominant myotonia congenita in muscle associated with myotonia congenita
20) Confidence 0.01 Published 1991 Journal Neuromuscul. Disord. Section Abstract Doc Link 1668369 Disease Relevance 0.57 Pain Relevance 0.21

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox